In NAFLD, levels of HO-1 are decreased, possibly through alterations in the levels of BACH1, leading to increased ROS production and inflammation, both of which contribute to enhanced triglyceride storage and reductions in glycogen (Figure 1). The gene discussed is BACH1; the disease is metabolic dysfunction-associated steatotic liver disease.